![]() |
|
|
Food Science and Human Nutrition Department, University of Florida, Gainesville, Florida 32611-0370
3To whom correspondence should be addressed at P.O. Box 110370, Newell Drive, Food Science and Human Nutrition Department, Gainesville, FL 32611-0370. E-mail: jfgy{at}ufl.edu
| ABSTRACT |
|---|
|
|
|---|
KEY WORDS: folate bioavailability fortification absorption
| INTRODUCTION |
|---|
|
|
|---|
|
Folate bioavailability in large part is governed by the extent of
intestinal absorption. Polyglutamyl folates, which constitute much of
naturally occurring food folate, must undergo enzymatic deconjugation
in the small intestine before absorption. This reaction is catalyzed
primarily by a pteroylpolyglutamate hydrolase associated with the
jejunal brush border membrane (Halsted 1990
), with
possibly some contribution by hydrolase activity from pancreatic
secretion (Bhandari et al. 1990
). Absorption of
monoglutamyl folates occurs via a saturable transport process with
acidic pH optimum (Km = 13
µmol/L), and an apparently nonsaturable absorption mechanism also
functions when folate concentrations in intestinal contents exceed
510 µmol/L (Mason 1990
). Because of the existence of
two absorption processes, findings regarding folate bioavailability at
a certain dosage level may not be predictive of bioavailability at a
substantially higher or lower intake. The pH optimum for folate
transport is
5 (Mason 1990
), whereas the pH optimum
of enzymatic deconjugation is
67 (Halsted 1989). As
discussed later, physiological conditions or medications that alter the
pH of the upper small intestine could impair folate absorption. In
addition, the administration of excessively large doses of acidic foods
in bioavailability protocols, as in certain previous studies, could
also yield results that do not reflect the bioavailability of more
normal doses.
| Methods in folate bioavailability |
|---|
|
|
|---|
There are many approaches that have yielded information regarding
folate bioavailability. Several animal models are suitable for
conducting bioassays to evaluate folate bioavailability, most commonly
using rats or, to a lesser extent, chicks. Although these procedures
have been used quite extensively, this author recommends that their use
be discontinued because their relevance to folate bioavailability in
human nutrition has not been established. In addition, it is likely
that conclusions reached from rat or chick bioassays regarding the
utilization of dietary polyglutamyl folates would not be predictive of
bioavailability in humans because of the well-documented
differences in the mechanism of intestinal folate deconjugation among
rats, chickens and humans, as reviewed previously (Gregory 1995
, Halsted 1990
). In addition, several other
conceptual and practical characteristics of animal bioassays limit
their relevance to human nutrition, including: 1) the need
to administer test doses in dry powdered form blended into basal diets,
which differs markedly from the form of food consumed by humans,
2) basal diets used in rat bioassays contain an oral
antibiotic to suppress intestinal microflora and their endogenous
folate production and 3) certain foods or dietary
supplements intended for human use cannot be tested in an animal model
(e.g., the absorption of folic acid from a commercial vitamin pill
cannot be evaluated in a rat or chick).
Human subjects: short-term protocols.
The bioavailability of folate from dietary sources and supplements
often can be determined with short-term protocols based on
measurement of the change in plasma or serum folate and/or urinary
folate excretion. A limitation of such methods is their relative
insensitivity, which makes these protocols suitable only for foods that
are relatively high in folate (at least
300 µg/dose). It is
important that a sufficient number of blood samples be taken to allow
reliable estimation of the area under the curve
(AUC).4
Several previous studies of folate bioavailability are probably flawed
because responses to test and reference doses were compared only on the
basis of change in plasma folate 12 h after the oral doses. It is
likely that the AUC for plasma/serum folate for a given folate dose
would be influenced by the folate status of the subjects. Thus,
subjects should be screened to ensure that they are in a similar state
of folate nutriture.
When using urinary folate excretion as a response indicator, it is
important to recognize that urinary excretion constitutes a small and
quite variable proportion of the ingested dose unless plasma folate
concentration exceeds the threshold of renal reabsorption
(Cooperman et al. 1970
, OKeefe et al. 1995
). To improve uniformity among subjects and enhance folate
excretion, Tamura and Stokstad (1973
) devised a
"saturation" protocol in which subjects consumed 2 mg folic acid
every other day before and between trials of bioavailability studies.
Saturation in this context does improve the precision of
bioavailability estimates; however, assessments of bioavailability
based on urinary excretion are still quite imprecise due to a high
degree of variability among subjects (Tamura and Stokstad 1973
).
Short-term protocols involving AUC measurements of plasma/serum folate
response have been effectively used to determine folate bioavailability
of high folate foods and various folate supplements and pharmaceutical
preparations. An example of a study of pharmaceutical folate
preparations is the investigation of 5-formyltetrahydrofolate compounds
(i.e., racemic leucovorin and the biologically active isomer
levoleucovorin) reported by DeVito et al. (1993
). In
separate trials, these investigators administered 15- and 30-mg doses
orally and intravenously, followed by the determination of total
reduced folate and 5-methyl-tetrahydrofolate concentrations in serial
blood samples. On the basis of total serum reduced folate, the 15- and
30-mg doses of levoleucovorin exhibited 74.3 ± 22.0% and 65.4
± 18.3% absolute bioavailability, respectively (means ± SD). Within each dose, oral and injected forms of
leucovorin exhibited equivalent AUC values on the basis of the
metabolite 5-methyl-tetrahydrofolate, which the authors interpreted as
evidence of bioequivalence. However, it should be recognized that at
this pharmacologic dose, metabolic pathways for the conversion of
levoleucovorin to 5-methyl-tetrahydrofolate would be saturated, which
would mask differences due to incomplete absorption.
After nutritionally relevant doses, the AUC of the rise in plasma
folate concentration permits direct comparisons of the relative
bioavailability of test meals and/or folate doses if doses are
sufficient to yield a measurable plasma/serum folate response (e.g.,
Bailey et al. 1988
, Fenech et al. 1999
,
Pietrzik et al. 1990
, Prinz-Langenohl et al. 1999
). In this regard, a dose-response study by
Bailey et al. (1988
) suggested that oral doses of 250
µg yielded a weak, imprecise response and that doses approaching 400
µg are needed to yield suitable precision. In contrast,
Pietrzik et al. (1990
) showed a measurable AUC after
doses of at least 150 µg, and several studies with
300 µg
available folate have shown reasonably precise measurement of AUCs for
plasma/serum folate. Protocols with more subjects have more statistical
power, and thus are suitable for use with lower doses. In a typical
application of this technique, oral doses of 300600 g spinach yielded
an AUC response in the same general range as that observed after a
400-µg dose of folic acid (Prinz-Langenohl et al. 1999
). The results of this study also showed nonlinearity in
response, i.e., the 300- and 600-g spinach doses yielded AUC values of
41.4 ± 19.4 and 71.2 ± 24.0 h/(nmol · L), respectively
(means ± SD). This suggests that relative
bioavailability may change as a function of size of the test meal,
which also suggests that the ideal experimental design should involve
several dosage levels of the test food substance.
Short-term studies of bioavailability based on only one or two plasma
values after the dose should be viewed cautiously. Unless the full time
course is evaluated through an analysis of serial blood samples, one
cannot determine whether differences in response are due to variation
in the rate or extent of absorption
(Gregory 1988
).
Human subjects: long-term protocols.
Long-term protocols of typically 36 wk duration are suitable for comparative studies of diets that differ in the source of folate. Consequently, if the total folate contents of test diets were equivalent, then any difference in final folate status of subjects would be due to a difference in folate bioavailability. In such protocols, serum folate is the most responsive indicator, whereas plasma homocysteine reflects differences in folate status within several weeks of intake. Erythrocyte folate changes in response to folate intake more slowly because <1% of circulating erythrocytes is replaced daily, and most of erythrocyte folate deposition occurs during erythropoiesis. A conceptual advantage of long-term protocols is the fact that the response is based on the aggregate utilization of folate in all meals consumed. Although such protocols are more lengthy and expensive than short-term procedures, they also permit assessment of bioavailability in diets that may not be compatible with AUC measurements.
Several important examples illustrate the use of long-term
protocols in studies of folate bioavailability (Brouwer et al. 1999
, Colman 1982
, Cuskelly et al. 1996
, Malinow et al. 1998
, Sauberlich et al. 1987
). Ideally, such a protocol involves all of the
subjects consuming the same basal diet, with various treatment groups
chronically consuming either a source of supplemental folic acid (or
other chronic reference) dose or a test food material. In the case of
the study of Brouwer et al. (1999
), subjects consumed
either supplemental folic acid or various fruits and vegetables, and
plasma folate and homocysteine concentrations were monitored. This
protocol indicated
6090% bioavailability of the folate from
fruits and vegetables, relative to folic acid. In contrast, the study
by Cuskelly et al. (1996
), whereas not designed as a
bioavailability study per se, compared the efficacy of a folic acid
supplement, fortified foods and high folate foods. On the basis of
erythrocyte folate response during the 3-mo trial, the fortified foods
were similar to the supplement in folate bioavailability, both of which
greatly exceeded the response observed with the high folate foods that
were examined.
| Isotopic methods |
|---|
|
|
|---|
For any isotopic study, especially when two or more labeled tracers are
used, validation studies must be conducted to establish that:
1) analytical methods provide accurate measurement of
the labeled tracer(s) and metabolite(s), 2) there is no
loss of label during metabolism, analytical preparation, purification
steps and quantification (e.g., gas chromatography-mass
spectrometry procedures) and 3) there is equivalent
metabolic behavior among various tracer forms and the unlabeled vitamin
species. When deuterium or tritium labeling is used, in which bond
energies and rates of dissociation and/or exchange may differ from
unlabeled hydrogen (1H), it is essential that labeling be
in metabolically and chemically inert components of the molecule.
Often, bioavailability studies involve a dual-tracer design, so
equivalent metabolic and chemical behavior of tracers at all stages of
metabolism and analysis is critical. In this regard, equivalent
behavior of [3',5'-2H2],
[glutamate-2H4] and
[glutamate-13C5] forms of
stable isotope-labeled folic acid has been demonstrated under
conditions of use in short-term bioavailability protocols
(Gregory et al.1990
, Rogers et al.1997
).
Since the late 1980s, studies using dual-tracer protocols with
stable isotope-labeled folates have permitted investigation of many
aspects of folate bioavailability in humans. These generally have
involved short-term studies in which relative bioavailability
between tracers or among experimental groups is assessed using urinary
excretion of labeled folates for 2448 h after dosing. Analyses of
urinary folates were initially performed in our studies because gas
chromatography-mass spectrometry procedures of the mid-1980s were
only marginally suitable to measure labeling of plasma folate. Urinary
excretion of folate in normal renal function is primarily a function of
plasma folate concentration. The short-term urinary excretion of a
folate tracer depends in large part on the folate status of the
subjects; it is a small and variable fraction of the dose at typical
folate intakes of 200400 µg. A saturation protocol that is a
modification of that devised by Tamura and Stokstad (1973
) increases the excretion of labeled folate and reduces
between-subject variability. If subjects are in approximately the
same folate status, it is possible to conduct bioavailability studies
without the saturation protocol (Pfeiffer et al. 1997
).
This eliminates any question regarding an influence of elevated folate
status on bioavailability (Gregory 1997
), although there
is consequentially reduced precision.
In an effort to improve the precision by normalizing for variation in
urinary excretion, an injected reference dose has been used in several
isotopic bioavailability protocols. A typical bioavailability protocol
using this approach would involve oral administration of
[13C5]folic acid and a bolus intravenous
injection of [2H2]folic acid. In such a
protocol, the response variable used is a normalized excretion, i.e.,
excretion of labeled folate derived from the oral dose divided by
excretion derived from the injected dose (Gregory et al. 1991 and 1992
, Pfeiffer et al. 1997
).
In typical pharmacological studies of drug or nutrient bioavailability,
a comparison of the plasma AUC derived from oral and injected doses
allows the determination of absolute bioavailability. Rogers et al. (1997
) tested this approach for moderate doses of folate:
400 µg oral [13C5]folic acid and 100 µg
[2H2]folic acid. The AUC response for
labeling of plasma folate, when adjusted for the difference in dose,
was
15 times greater for intravenous folates than for oral folates.
This suggests that absolute bioavailability cannot be readily
determined by this conventional protocol because of the extensive
hepatic uptake and enterohepatic recycling of absorbed folates derived
from the oral dose. These findings are in marked contrast to those
typically found using much larger oral and injected doses of nonlabeled
folates (e.g., DeVito et al. 1993
). In view of this
limitation of the determination of plasma AUC and in view of the
relative ease of urine collection and analysis, it appears that
analysis of urinary excretion of labeled folates in a well-designed
protocol is the best approach in many applications of stable isotopic
techniques.
| In vitro methods |
|---|
|
|
|---|
33%).
Despite this significantly incomplete bioavailability of the
polyglutamyl tracer added to orange juice, orange juice is still a good
source of available folate because of the high
concentration of folate that has reasonably high
bioavailability (Wei et al. 1996Seyoum and Selhub (1999) devised an alternative approach to the in vitro estimation of folate bioavailability. In this method, a food extract containing naturally occurring folates is incubated under conditions designed to simulate gastric acid, followed by neutralization and exposure to intestinal conjugase activity. A "bioavailability index" is calculated on the basis of both in vitro retention (i.e., stability) and extent of deconjugation. Of interest was the fact that significant correlation was obtained between the in vitro bioavailability index and apparent in vivo bioavailability derived from the human studies of Tamura and Stokstad (1973). Further work is needed to assess and confirm the merits of in vitro prediction of folate bioavailability.
| Population-based methods |
|---|
|
|
|---|
| Key findings that shape modern views of folate bioavailability |
|---|
|
|
|---|
As reviewed previously (Gregory 1995
), several
studies have reported differences in the apparent bioavailability of
synthetic forms of individual folates with inconsistent results. An
isotopic investigation showed
30% lower response to the
biologically active isomer of tetrahydrofolate than that of three other
reduced folates (Gregory et al. 1992
). However, urinary
excretion of labeled folates derived from
[2H2]folic acid exceeded
that of all reduced folates. This is now interpreted as indicating
lesser in vivo retention of folic acid when consumed by
folate-saturated subjects at moderately high doses. It is likely
that differences among monoglutamyl folates reported previously for
moderately high doses (at least several hundred micrograms) are due to
differences in hepatic uptake, enterohepatic circulation, tissue
distribution and urinary reabsorption. Lower doses of radiolabeled
folic acid, 5-methyl-tetrahydrofolate and 5-formyl-tetrahydrofolate in
rats showed essentially complete absorption, similar short-term
distribution and metabolism and in vivo kinetics (Bhandari and Gregory 1992
). Thus, it appears that there is little inherent
difference among the various folate species when consumed at low doses.
An additional aspect of dose-response behavior in folate
bioavailability is now apparent, i.e., metabolic capacity. Single doses
of folic acid of more than several hundred micrograms exceed the
metabolic capacity for reduction and methylation (Kelly et al. 1997
, Lucock et al. 1989
).
Monoglutamyl versus polyglutamyl folates.
The bioavailability of polyglutamyl folates relative to monoglutamyl
forms has been extensively examined for many years and was reviewed by
Gregory (1995
). Long-chain (n = 57) polyglutamyl folates are available for absorption and metabolic
utilization only to the extent that they undergo enzymatic
deconjugation in the small intestine. Thus, incomplete bioavailability
of doses of synthetic or purified naturally occurring polyglutamyl
folates would be indicative of incomplete deconjugation. Of the many
studies in which monoglutamyl and polyglutamyl folates are compared,
relative bioavailability values range from
50 to 100%, with an
average of these studies of
75% bioavailability for long-chain
polyglutamyl species (Gregory 1995
). The reason for this
broad range is unclear; possibly there is a dose dependence reflective
of the kinetics of deconjugation, possibly inhibitors (e.g., ascorbate)
are also involved and in some studies analytical error cannot be ruled
out. In addition, studies based only on short-term changes in
plasma folate concentration may underestimate the bioavailability of
polyglutamyl folates if absorption rate, rather than extent, differs. A
number of well-conducted studies that indicate approximately
equivalent bioavailability of monoglutamyl and polyglutamyl folates
strongly suggest that the human small intestine has sufficient
pteroylpolyglutamate hydrolase activity to deconjugate polyglutamyl
folates fully in the absence of food materials. For example, as
described later, a stable isotopic study that compared simultaneous
doses of [2H2]folate
hexaglutamate with
[2H4]folate monoglutamate
indicated equivalent bioavailability in five sequential trials (two
control trials with aqueous folate solutions administered, along with
those in which folates were administered after blending with tomatoes,
lima beans or a citrate buffer) in folate-saturated humans
(Wei et al. 1996
). A recently identified genetic
polymorphism of intestinal pteroylpolyglutamate hydrolase (glutamate
carboxypeptidase II) is associated with impaired absorption of dietary
folate and, hence, lower folate status in persons having the less
active form of the enzyme (Devlin et al. 2000
).
| Bioavailability of naturally occurring and added folate in foods |
|---|
|
|
|---|
50% is
quite imprecise. Cuskelly et al. (1996
It should be recognized that not all food sources of folate exhibit
poor bioavailability. For example, Brouwer et al. (1999
)
found that an assortment of fruits and vegetables exhibited 6090%
bioavailability relative to folic acid. Moderately high bioavailability
of spinach folate, although not quantified as a percentage, was
reported by Prinz-Langenohl et al. (1999
). Rhode et al. (1983
) and Neuhouser et al. (1998
)
reported evidence of incomplete but reasonably high bioavailability of
naturally occurring folate in orange juice.
The influence of diet composition and food selection on the overall
bioavailability of dietary folate has not been determined and currently
cannot be predicted. In addition, the reasons behind the
often-incomplete bioavailability of individual foods also are
unclear, although it can now be proposed to be a function of three main
factors. First, it is likely that foods such as orange juice have
partially incomplete bioavailability of polyglutamyl folates due to the
presence of natural inhibitors (Wei et al. 1996
,
Wei and Gregory 1998
). Second, in vitro evidence
reported by Seyoum and Selhub (1998) strongly suggests
that some chemical instability of reduced folate in the digestive
system before absorption also accounts for some variation in
bioavailability among foods. Third, it appears that entrapment of
folates in the cellular structure of plant materials partially
inhibits their absorption (Castenmiller et al. 2000
, van het Hof et al. 1999
).
Several lines of evidence indicate higher bioavailability of added
folic acid than naturally occurring folates in many foods. As stated
previously, the study by Cuskelly et al. (1996
)
indicates similar bioavailability of folic acid in fortified foods and
dietary supplements. In addition, labeled folate added to various
cereal-grain foods also exhibited bioavailability similar to that
of folic acid in aqueous solution (Pfeiffer et al. 1997
), and folate in fortified breakfast cereal has been shown
to be effective in raising folate status in humans (Malinow et al. 1998
).
| Bioavailability of folate in dietary supplements |
|---|
|
|
|---|
Another issue is the influence of food on the bioavailability of folic
acid in supplements. In this regard, the influence of a light breakfast
meal on the absorption of folic acid was examined in a stable isotopic
study with humans (Pfeiffer et al. 1997
). Consumption of
the folate tracer with the light breakfast meal caused
15% lower
bioavailability than that observed when consumed without food. The
influence of food on the dissolution of various types of supplements
has not been determined.
| Dietary folate equivalents and assumptions regarding bioavailability |
|---|
|
|
|---|
| Physiological and pharmacological factors that affect folate bioavailability |
|---|
|
|
|---|
5.0
(Mason 1990
The major impetus behind the recently implemented addition of folate to
cereal grain foods in the United States is the finding that risk of
neural tube defect (NTD) in pregnancy is reduced in proportion to
folate nutritional status (Molloy et al. 1999
,
Scott et al. 1995
). The reason for the protective effect
of folate has not been identified. Several groups have investigated
intestinal absorption is related to the risk of NTD. Neuhouser et al. (1998
) examined short-term plasma response in women
who had a previous NTD-affected pregnancy and controls in response
to either 400 µg folic acid or 0.95 L orange juice. Although the
response of this study is ambiguous because of possible differences in
folate status of these patients and controls, a statistically lower AUC
response to the folic acid supplements was seen in the NTD case women.
Davis et al. (1995
) examined urinary excretion after an
oral [2H4]folate dose to
NTD case women and controls in a standardized folate-saturation
protocol. A slightly but not significantly lower response was observed
in NTD case women. This observation has been confirmed and extended in
a recent study (Boddie et al. 2000
). These results suggest the need for
further examination of whether intestinal absorption of folate is
somewhat impaired in women at risk of an NTD-affected pregnancy.
One hypothesis is that this may be an indicator of impaired folate
transport in other tissues at critical stages of development.
| Nutrient interactions that affect folate bioavailability |
|---|
|
|
|---|
| Research needs |
|---|
|
|
|---|
Bioavailability of naturally occurring dietary folate.
A major research priority is attain an improved understanding of the bioavailability of naturally occurring folate and its relation to diet composition. This is particularly important in populations with little intake of fortified foods and dietary supplements.
Influence of food preparation methods on bioavailability of naturally occurring folate.
Can food processing or preparation techniques significantly alter bioavailability by altering the physical properties (e.g., integrity of plant cell wall components)?
Concept of dietary folate equivalents for expression of dietary allowances and description of food folate content.
Further quantification and fine tuning of assumptions regarding bioavailability of naturally occurring and synthetic folate are needed to improve the precision and utility of this approach to assessing folate intake.
Health effects of various diets and forms of folate.
Continued research is needed to more fully assess the relative effect of diet composition variables, relative bioavailability of folate in such diets and relative impact on health of various foods and forms of supplemental folate.
Analytical methodology.
The bioavailability of a nutrient cannot be assessed without accurate analytical data. Better analytical methods are needed for the measurement of total folate in diets, including naturally occurring folates and added folic acid. In addition, improvement in food composition data for folate is an urgent need.
Bioavailability and health.
A number of questions should be addressed in which changes in folate bioavailability may be associated with direct heath effects, including possible differences associated with populations at particular risk of NTD-affected pregnancy, segments of the population in whom digestive changes are common (e.g., achlorhydria in elderly persons) and the impact of commonly prescribed prescription drugs or over-the counter medications.
Dietary supplements.
Improved understanding of the relationships among formulation variables, rates of dissolution and solubilization in in vitro testing and in vivo bioavailability are high priorities.
Population-based studies.
An examination of epidemiological and population-based data will provide an alternative and powerful means of examining the role of bioavailability as associated with many aspects of human health, food selection patterns, fortification methods and effects, disease effects on folate bioavailability and nutritional status and effects of common genetic polymorphisms.
| FOOTNOTES |
|---|
2 Florida Agricultural Experiment Station Journal Series No. R-08035. Supported in part by U.S. Department of Agriculture NRICGP Grants 91-37200-6305 and 94-37200-0604. ![]()
4 Abbreviation used: AUC, area under the curve; NTD, neural tube defect. ![]()
| REFERENCES |
|---|
|
|
|---|
1. Anderson S. A., Talbot J. M. A Review of Folate Intake, Methodology, and Status 1981 Life Sciences Research Office, Federation of American Societies for Experimental Biology Bethesda, MD.
2.
Babu S., Srikantia S. G. Availability of folates from some foods. Am. J. Clin. Nutr. 1976;29:376-379
3. Baggott J. E., Morgan S. L., Taisun H. A., Vaughn W. H., Hine R. J. Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem. J. 1992;282:197-202
4. Bailey L. B. Factors affecting folate bioavailability. Food Technol 1988;42:206-210
5.
Bhandari S. D., Gregory J. F. Inhibition by selected food components of human and porcine intestinal pteroylpolyglutamate hydrolase activity. Am. J. Clin. Nutr. 1990;51:87-94
6. Bhandari S. D., Gregory J. F. Folic acid, 5-methyl-tetrahydrofolate, and 5-formyl-tetrahydrofolate exhibit equivalent intestinal absorption, metabolism, and in vivo kinetics in rats. J. Nutr. 1992;122:1847-1854
7. Bhandari S. D., Gregory J. F., Renuart D. R., Merritt A. M. Properties of pteroylpolyglutamate hydrolase in pancreatic juice of the pig. J. Nutr. 1990;120:467-475
8.
Boddie A. M., Dedlow E. R., Nackashi J. A., Opalko F. J., Kauwell G.P.A., Gregory J. F., Bailey L. B. Folate absorption in women with a history of neural tube defect-affected pregnancy. Am. J. Clin. Nutr. 2000;72:154-158
9.
Brouwer I. A., van Dusseldorp M., West C. E., Meyboom S., Thomas C.M.G., van het Hof K., Eskes T.K.A.B., Houtvast J.G.A.J., Steegers-Theunissen R.P.M. Dietary folate from vegetables and citrus fruit decreases plasma homocysteine concentrations in humans in a dietary controlled trial. J. Nutr. 1999;129:1135-1139
10. Buchholz B. A., Arjomand A., Dueker S. R., Schneider P. D., Clifford A. J., Vogel J. S. Intrinsic erythrocyte labeling and attomole pharmacokinetic tracing of 14C-labeled folic acid with accelerator mass spectrometry. Anal. Biochem. 1999;269:348-352[Medline]
11.
Butterworth C. E., Tamura T. Folic acid safety and toxicity: a brief review. Am. J. Clin. Nutr. 1989;50:353-358
12. Castenmiller J. J., van De Poll C. J., West C. E., Brouwer I. A., Thomas C. M., van Dusseldorp M. Bioavailability of folate from processed spinach in humans. Effect of food matrix and interaction with carotenoids. Ann. Nutr. Metals. 2000;44:163-169
13. Clifford A. J., Arjomand A., Dueker S. R., Schneider P. D., Buchholz B. A., Vogel J. S. The dynamics of folic acid metabolism in an adult given a small tracer dose of 14C-folic acid. Adv. Exp. Med.Biol. 1998;445:239-251[Medline]
14. Colman N. Addition of folic acid to staple foods as a selective nutrition intervention strategy. Nutr. Rev. 1982;40:225-233[Medline]
15. Cooperman J. M., Pesci-Bourel A., Luhby A. L. Urinary excretion of folic acid activity in man. Clin. Chem. 1970;16:375-381
16. Cuskelly G. J., McNulty H., Scott J. M. Effect of increasing dietary folate on red-cell folate: implications for prevention of neural tube defects. Lancet 1996;347:657-659[Medline]
17.
Davis B. A., Bailey L. B., Gregory J. F., Toth J., Dean J., and Stevenson R. E. Folic acid absorption in women with a history of a neural tube defect-affected pregnancy. Am. J. Clin. Nutr. 1995;62:782-784
18.
Devlin A. M., Ling E. H., Peerson J. M., Fernando S., Clarke R., Smith A. D., Halsted C. H. Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia. Hum. Mol. Genet. 2000;9:2837-2844
19. DeVito J. M., Kozloski G. D., Tonelli A. P., Johnson J. B. Bioequivalence of oral and injectable levoleucovorin and leucovorin. Clin. Pharm. 1993;12:293-299[Medline]
20.
Fenech M., Noakes M., Clifton P., Topping D. Aleurone flour is a rich source of bioavailable folate in humans. J. Nutr. 1999;129:1114-1119
21.
Ghishan F. K., Said H. M., Wilson P. C., Murrell J. E., Greene H. L. Intestinal transport of zinc and folic acid: a mutual inhibitory effect. Am. J. Clin. Nutr. 1986;43:258-262
22. Gregory J. F. Recent developments in methods for the assessment of vitamin bioavailability. Food Technol 1988;42(10):230-238
23. Gregory J. F. Chemical and nutritional aspects of folate research: analytical procedures, methods of folate synthesis, stability and bioavailability of dietary folates. Advances in Food and Nutrition Research 1989 Academic Press San Diego, CA.
24. Gregory J. F. The bioavailability of folate. Bailey L. eds. Folate: Nutritional and Clinical Perspectives 1995:195-235 Marcel Dekker New York.
25. Gregory J. F. Bioavailability of folate. Eur. J. Clin. Nutr. 1997;51(Suppl.):S54-S59
26.
Gregory J. F., Bailey L. B., Toth J. P., and Cerda J. J. Stable isotope methods for assessment of folate bioavailability. Am. J. Clin. Nutr. 1990;51:212-215
27.
Gregory J. F., Bhandari S. D., Bailey L. B., Toth J. P., Baumgartner T. G., and Cerda J. J. Relative bioavailability of deuterium-labeled monoglutamyl and hexaglutamyl folates in human subjects. Am. J. Clin. Nutr. 1991;53:736-740
28.
Gregory J. F., Bhandari S. D., Bailey L. B., Toth J. P., Baumgartner T. G., and Cerda J. J. Relative bioavailability of deuterium-labeled monoglutamyl tetrahydrofolates and folic acid in human subjects. Am. J. Clin. Nutr. 1992;55:1147-1153
29. Gregory J. F., and Toth J. P. Chemical synthesis of deuterated folate monoglutamate and in vivo assessment of urinary excretion of deuterated folates in man. Anal. Biochem. 1988;170:94-104[Medline]
30. Halsted C. H. Intestinal absorption of dietary folates. Picciano M. F. Stokstad E.L.R. Gregory J. F. eds. Folic Acid Metabolism in Health and Disease 1990:23-45 Wiley-Liss New York.
31. Institute of Medicine Folate. Dietary Reference Intakes. Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline 1998:81868 Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, National Academy Press Washington, D.C.
32. Kauwell G.P.A., Bailey L. B., Gregory J. F., Bowling D. W., and Cousins R. J. Zinc status is not adversely affected by folic acid supplementation and zinc intake does not impair folate utilization in human subjects. J. Nutr. 1995;125:66-72
33.
Keating J. N., Wada L., Stokstad E. L., King J. C. Folic acid: effect on zinc absorption in humans and in the rat. Am. J. Clin. Nutr. 1987;46:835-839
34.
Kelly P., McPartlin J., Goggins M., Weir D. G., Scott J. M. Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. Am. J. Clin. Nutr. 1997;65:1790-1795
35.
Lewis C. J., Crane N. T., Wilson D. B., Yetley E. A. Estimated folate intakes: data updated to reflect food fortification, increased bioavailability, and dietary supplement use. Am. J. Clin. Nutr. 1999;70:198-207
36. Lucock M., Wild J., Smithells R., Hartley R. Biotransformation of pteroylmonoglutamic acid during absorption: implications of Michaelis-Menten kinetics. Eur. J. Clin. Nutr. 1989;43:631-635[Medline]
37.
Malinow M. R., Duell P. B., Hess D. L., Anderson P. H., Kruger W. D., Phillipson B. E., Gluckman R. A., Block P. C., Upson B. M. Reduction of plasma homocyst(e)ine levels by breakfast cereal fortified with folic acid in patients with coronary heart disease. N. Engl. J. Med. 1998;338:1009-1015
38. Mason J. B. Intestinal transport of monoglutamyl folates in mammalian systems. Picciano M. F. Stokstad E.L.R. Gregory J. F. eds. Folic Acid Metabolism in Health and Disease 1990:47-64 Wiley-Liss New York.
39.
Milne D. B., Canfield W. K., Mahalko J. R., Sandstead H. H. Effect of oral folic acid supplements on zinc, copper, and iron absorption and excretion. Am. J. Clin. Nutr. 1984;39:535-539
40. Molloy A. M., Mills J. L., Kirke P. N., Weir D. G., Scott J. M. Folate status and neural tube defects. Biofactors 1999;10:291-294[Medline]
41. Neuhouser M. L., Beresford S. A., Hickok D. E., Monsen E. R. Absorption of dietary and supplemental folate in women with prior pregnancies with neural tube defects and controls. Am. Coll. Nutr. 1998;17:625-630
42. OKeefe C. A., Bailey L. B., Thomas E. A., Hofler S. A., Davis B. A., Cerda J. J., Gregory J. F. Controlled dietary folate affects folate status in nonpregnant women. J. Nutr. 1995;125:2717-2725
43. Pfeiffer C. M., Gregory J. F. Preparation of stable-isotopically labeled folates for in vivo investigation of folate absorption and metabolism. Methods Enzymol 1997;281:106-116[Medline]
44.
Pfeiffer C. M., Rogers L. M., Bailey L. B., Gregory J. F. Absorption of folate from fortified cereal-grain products and of supplemental folate consumed with or without food determined using a dual-label stable-isotope protocol. Am. J. Clin. Nutr. 1997;66:1388-1397
45. Pietrzik K., Hages M., Remer T. Methodological aspects in vitamin bioavailability testing. J. Micronutr. Anal. 1990;7:207-222
46.
Prinz-Langenohl R., Bronstrup A., Thorand B., Hoges M., Pietrzik K. Availability of food folate in humans. J. Nutr. 1999;129:913-916
47. Rhode B. M., Cooper B. A., Farmer F. A. Effect of orange juice, folic acid, and oral contraceptives on serum folate in women taking a folate-restricted diet. J. Am. Coll. Nutr. 1983;2:221-230[Abstract]
48.
Rimm E. B., Willett W. C., Hu F. B., Sampson L., Colditz G. A., Manson J. E., Hennekens C., Stampfer M. J. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. J. Am. Med. Assoc. 1998;279:359-364
49. Rodriquez M. S. A conspectus of research on folacin requirements of man. J. Nutr. 1978;108:1983-2075
50.
Rogers L. M., Pfeiffer C. M., Bailey L. B., and Gregory J. F. A dual-label stable-isotopic protocol is suitable for determination of folate bioavailability: Evaluation of urinary excretion and plasma folate kinetics of intravenous and oral doses of [13C5] and [2H2]folic acid. J. Nutr. 1997;127:2321-2327
51. Russell R. M., Dhar G. J., Dutta S. K., Rosenberg I. H. Influence of intraluminal pH on folate absorption: studies in control subjects and in patients with pancreatic insufficiency. J. Lab. Clin. Med. 1979;93:428-436[Medline]
52. Russell R. M., Kransinski S. D., Samloff I. M., Jacob R. A., Hartz S. C., Brovender S. R. Folic acid malabsorption in atrophic gastritis: possible compensation by bacterial folate synthesis. Gastroenterology 1986;91:1476-1482[Medline]
53. Sauberlich H. E., Kretsch M. J., Skala J. H., Johnson H. L., Taylor P. C. Folate requirement and metabolism in nonpregnant women. Am. J. Clin. Nutr. 1987;46:1016-1028